All > American Chronic Pain > Chronic Pain

[11C]-NOP46 for Chronic Pain

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Chronic Pain[11C]-NOP46 - Drug
Eligibility
18 - 90
All Sexes
What conditions do you have?
Select

Study Summary

This study is evaluating whether a new radioactive chemical may help doctors better understand how the brain works.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
PET/CT Scan with FNP-59
1
Radiation Therapy
1
Radiotracer

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 48 hours post-scan

48 hours post-scan
Occurrence of Physiologic Effects of Single Micro-dose of [11C]-NOP46
Uptake ratio for site with pain is >1

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
PET/CT Scan with FNP-59
1
Radiation Therapy
1
Radiotracer

Trial Design

2 Treatment Groups

Individuals with Focal Pain
1 of 2
Healthy Volunteers
1 of 2

Experimental Treatment

40 Total Participants · 2 Treatment Groups

Primary Treatment: [11C]-NOP46 · No Placebo Group · Phase < 1

Individuals with Focal PainExperimental Group · 2 Interventions: PET/CT scan, [11C]-NOP46 · Intervention Types: Radiation, Drug
Healthy VolunteersExperimental Group · 2 Interventions: PET/CT scan, [11C]-NOP46 · Intervention Types: Radiation, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PET/CT scan
2013
Completed Phase 1
~340

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 48 hours post-scan

Who is running the clinical trial?

Akiva MintzLead Sponsor
Akiva Mintz, MD, PhDPrincipal Investigator - Columbia University
Columbia University

Eligibility Criteria

Age 18 - 90 · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top